Elos Medtech to enlarge plant in Skara

Elos Medtech Microplast, a company in the Elos Group, will be expanding its plant in Skara by 1,500 square metres due to increased demand for injection-moulded plastic components from customers in the medical-technology sector.

During 2014, Elos Medtech Microplast invested in sterile rooms for assembly, packaging and production in a sterile room environment. Production in Skara is largely automated and the operation is ISO 13485 certified.

The company’s MD, Mathias Andersson, says: “The increase in our market activities and a distinct business strategy combined with being part of Elos Medtech Group have aroused curiosity among our customers. At the same time, Elos Medtech Microplast already has an outstanding reputation and has displayed extremely good expertise and experience in technically demanding plastics over the years, while delivering excellent quality and precision. Together with our customers, we have developed a joint plan to increase cooperation in the years ahead. This has resulted in several major projects, which will constitute a key aspect of the company’s growth in the next coming years,” summarises Mathias Andersson.

When the expanded plant is completed at the end of 2015, capacity will be doubled compared with the current situation. This will create a platform which is necessary for the expected growth the coming years.

“We are focusing 100% on medical-technology customers and, together with other companies within Elos Medtech, we will have a unique offering that enables us to provide turnkey solutions for customers in selected segments,” says Mathias Andersson.

Elos Medtech is one of Europe’s leading business partners in the development and production of precision products and components used in medical technology, such as dental and orthopaedic implants and instruments. Operations are conducted at facilities in Sweden, Denmark and China. Customers consist primarily of international medical-technology companies.

Elos Group’s turnover is approximately MSEK 400 and has about 400 employees. The Group is traded on NASDAQ Stockholm AB since 1989. The Elos B share is classified as a Health Care company on the Small Cap list.

Lidköping, January 20, 2015

Elos AB (publ)

For further information, please contact: Göran Brorsson, CEO, phone +46 510 48 43 65, mobile +46 705 11 78 60, e-mail goran.brorsson@elos.se or Mathias Andersson, Managing Director Elos Medtech Microplast, phone +46 732 70 99 65 mathias.andersson@elosmedtech.com

For additional information Elos Group, visit www.elos.se  

The information of this press release is of the kind that Elos AB (publ) has to make public according to the Securities Market Act and/or the Financial Instruments Trading Act. The information was made public on 20 January, 2015 at 08:00 a.m. (CET).


About Us

Elos Medtech is one of Europe's leading development and production partners for medical technology products and components, such as dental and orthopaedic implants and instruments. The operations are conducted at facilities in Sweden, Denmark, China and USA. Customers are mainly internationally active medical technology companies in the market segments Dental Implant Systems, Diagnostics, Medical Devices and Trauma & Spine. Elos Medtech employs more than 500 people worldwide and generates revenue that exceeds MSEK 550. Elos Medtech has been traded on NASDAQ Stockholm AB since 1989. The Elos Medtech B share is classified as a Health Care company on the Small Cap list.


Documents & Links